Gabify, a healthtech startup specializing in neurodevelopmental care, has raised $175,000 in a pre-seed funding round led by Inflection Point Ventures (IPV). The infusion of capital is bolstered by an additional ₹25 lakh grant received under the Nidhi Seed Support Scheme from GHRTBI.
The company plans to utilize the new capital to accelerate clinical validation, enhance its proprietary technology stack, and expand its core team. With a roadmap set for 2028, Gabify aims to impact one million children through a multi-channel approach involving B2B, B2C, and CSR-led initiatives.
Revolutionizing Early Intervention
Founded in 2023 by Sahil Chopra, Prachi Sood, and Vasyl Leshchuk, Gabify addresses the critical gap in early screening and therapy management for speech and neurodevelopmental disorders, including Autism and ADHD.
The startup’s core innovation lies in its dual AI system, which integrates:
-
Voice Analysis: Assessing speech patterns and linguistic development.
-
Vision Analysis: Monitoring facial expressions and behavioral indicators.
-
Clinical Oversight: Utilizing a “human-in-the-loop” model to ensure all AI-driven assessments align with validated clinical parameters.
Market Traction and Recognition
Gabify’s platform has already seen practical application, having undergone testing across more than 35 preschools and daycare centers. Currently, the technology is being deployed within a network of schools, hospitals, and specialized clinics.
The startup’s potential has not gone unnoticed in the venture ecosystem. Beyond the IPV investment, Gabify was selected as one of the top 10 startups under DreamDeal, an initiative by Shaadi.com founder Anupam Mittal. It is also an active participant in Inflection Point Ventures’ IdeaSchool program.
By digitizing the screening process, Gabify aims to lower the barrier for parents and educators to identify developmental delays early, ensuring children receive intervention during their most formative years.
By: Sandhya Bharti
